CNA – Britain’s medicines regulator has approved AstraZeneca’s antibody-based COVID-19 treatment for adults with poor immune response, marking a major step in the fight against the pandemic as infections surge globally amid the spread of the Omicron variant. More details in Friday’s Borneo Bulletin.
Borneo Bulletin is the leading English daily in the country. It was first published by Brunei Press. Today, Borneo Bulletin has become the foremost source of information on local and foreign affairs, and the region’s business news.
© 2013 Borneo Bulletin Online - The Independent Newspaper in Brunei Darussalam, Sabah and Sarawak
